Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
J Vasc Surg. 2023 Jan;77(1):9-19.e2. doi: 10.1016/j.jvs.2022.08.007. Epub 2022 Aug 15.
With increasing experience in fenestrated endovascular aneurysm repair (FEVAR) over time, devices designed to treat juxta-/pararenal aortic aneurysms have evolved in complexity to extend to more proximal landing zones and incorporate more target vessels. We assessed perioperative outcomes in patients who underwent juxta-/pararenal FEVAR with supraceliac vs infraceliac sealing in the Vascular Quality Initiative.
We identified all patients who underwent elective FEVAR (commercially available FEVAR and physician-modified endografts) for juxta-/pararenal aortic aneurysms in the Vascular Quality Initiative between 2014 and 2021. Supraceliac sealing was defined as proximal sealing in aortic zone 5, or zone 6 with a celiac scallop/fenestration/branch or celiac occlusion. Primary outcomes were perioperative and 3-year mortality. Secondary outcomes included completion endoleaks, in-hospital complications, and factors associated with 3-year mortality. We calculated propensity scores and used inverse probability-weighted Cox regression and logistic regression modeling to assess outcomes.
Among 1486 patients identified, 1246 patients (84%) underwent infraceliac sealing, and 240 patients (16%) underwent supraceliac sealing. Of the supraceliac patients, 74 (31%) had a celiac scallop, 144 (60%) had a celiac fenestration/branch, and 22 (9.2%) had a celiac occlusion (intentional or unintentional). After risk-adjusted analyses, there were no differences in perioperative mortality following supraceliac sealing compared with infraceliac sealing (2.3% vs 2.5%; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.26-1.8; P = .42), or 3-year mortality (12% vs 15%; HR, 0.89; 95% CI, 0.53-1.5; P = .67). Compared with infraceliac sealing, supraceliac sealing was associated with lower odds of type-IA completion endoleaks (odds ratio [OR], 0.24; 95% CI, 0.05-0.67), but higher odds of any complication (12% vs 6.9%; OR, 1.6; 95% CI, 1.01-2.5) including cardiac complications (5.5% vs 1.9%; OR, 2.6; 95% CI, 1.3-5.1), lower extremity ischemia (3.0% vs 0.9%; OR, 3.2; 95% CI, 1.02-9.5), and acute kidney injury (16% vs 11%; OR, 1.6; 95% CI, 1.05-2.3). Though non-significant, there was a trend towards higher risk of spinal cord ischemia following supraceliac sealing compared with infraceliac sealing (1.7% vs 0.8%; OR, 2.2; 95% CI, 0.70-6.4). There were no differences in bowel ischemia between groups (1.7% vs 1.5%; OR, 0.83; 95% CI, 0.24-1.23). A more proximal aneurysm disease extent was associated with higher 3-year mortality (HR zone 8 vs 9, 1.7; 95% CI, 1.1-2.5), whereas procedural characteristics had no influence.
Compared with sealing at an infraceliac level, supraceliac sealing was associated with lower risk of type IA endoleaks and similar mortality. However, clinicians should be aware that supraceliac sealing was associated with higher perioperative morbidity. Future studies with longer follow-up are needed to adequately assess durability differences to comprehensively weigh the risks and benefits of utilizing a higher sealing zone within the visceral aorta for juxta-/pararenal FEVAR.
随着血管腔内修复术(fenestrated endovascular aneurysm repair,FEVAR)经验的不断积累,治疗肾下/肾上腹主动脉瘤的器械在复杂性方面不断发展,以扩展到更近端的着陆区,并纳入更多目标血管。我们评估了血管质量倡议(Vascular Quality Initiative)中接受肾下/肾上腹 FEVAR 手术的患者的围手术期结局,这些患者在肾下/肾上腹 FEVAR 手术中采用了肾下腹主动脉以上(supraceliac)或肾下腹主动脉以下(infraceliac)的封闭方法。
我们在 2014 年至 2021 年期间,在血管质量倡议中确定了所有接受择期 FEVAR(商业上可用的 FEVAR 和经医生修改的内脏移植物)治疗肾下/肾上腹主动脉瘤的患者。肾下腹主动脉以上的封闭定义为主动脉区域 5 或区域 6 的近端封闭,或者有内脏动脉的扇贝/开窗/分支或内脏动脉闭塞。主要结局是围手术期和 3 年死亡率。次要结局包括完全性Ⅰ型内漏、住院并发症和与 3 年死亡率相关的因素。我们计算了倾向评分,并使用逆概率加权 Cox 回归和逻辑回归模型来评估结局。
在确定的 1486 例患者中,1246 例(84%)接受了肾下腹主动脉以下的封闭,240 例(16%)接受了肾下腹主动脉以上的封闭。在接受肾下腹主动脉以上封闭的患者中,74 例(31%)有内脏动脉扇贝,144 例(60%)有内脏动脉开窗/分支,22 例(9.2%)有内脏动脉闭塞(有意或无意)。在风险调整分析后,与肾下腹主动脉以下的封闭相比,肾下腹主动脉以上的封闭在围手术期死亡率(2.3%对 2.5%;风险比[HR],0.67;95%置信区间[CI],0.26-1.8;P=0.42)或 3 年死亡率(12%对 15%;HR,0.89;95%CI,0.53-1.5;P=0.67)方面没有差异。与肾下腹主动脉以下的封闭相比,肾下腹主动脉以上的封闭与较低的ⅠA型完全性内漏发生率(比值比[OR],0.24;95%CI,0.05-0.67)相关,但与较高的任何并发症发生率(12%对 6.9%;OR,1.6;95%CI,1.01-2.5)相关,包括心脏并发症(5.5%对 1.9%;OR,2.6;95%CI,1.3-5.1)、下肢缺血(3.0%对 0.9%;OR,3.2;95%CI,1.02-9.5)和急性肾损伤(16%对 11%;OR,1.6;95%CI,1.05-2.3)。虽然没有统计学意义,但与肾下腹主动脉以下的封闭相比,肾下腹主动脉以上的封闭有更高的脊髓缺血风险趋势(1.7%对 0.8%;OR,2.2;95%CI,0.70-6.4)。两组之间的肠缺血没有差异(1.7%对 1.5%;OR,0.83;95%CI,0.24-1.23)。更靠近腹主动脉的动脉瘤病变范围与更高的 3 年死亡率相关(区域 8 与 9 相比,HR 为 1.7;95%CI,1.1-2.5),而手术特征没有影响。
与在肾下腹主动脉以下封闭相比,肾下腹主动脉以上的封闭与较低的ⅠA型内漏风险和相似的死亡率相关。然而,临床医生应该意识到,肾下腹主动脉以上的封闭与更高的围手术期发病率相关。需要进行更长时间的随访研究,以充分评估耐久性差异,全面权衡在肾下/肾上腹 FEVAR 中利用更高的内脏主动脉封闭区域的风险和益处。